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Abstract
Recent public health emergencies have highlighted the unique vulnerabilities of pregnant women 
and infants to emerging health threats and the critical role of public health surveillance. 
Surveillance systems can collect critical data to measure the impact of a disease or disaster and can 
be used to inform clinical guidance and prevention strategies. These systems can also be tailored 
to collect data on vulnerable populations, such as pregnant women and their infants. Novel 
surveillance systems to assess risks and outcomes of pregnant women and infants have been 
established during public health emergencies but typically cease data collection once the public 
health response has ended, limiting our ability to collect data to understand longer-term outcomes. 
State-based birth defects surveillance systems are not available in all states, and no national 
surveillance system linking pregnancy exposure data to longitudinal outcomes for infants and 
children exists. In this report, we describe ongoing surveillance efforts to monitor congenital 
syphilis, Zika virus infection during pregnancy, and neonatal abstinence syndrome. We describe 
the need and rationale for an ongoing integrated surveillance system to monitor pregnant women 
and their infants and to detect emerging threats. We also discuss how data collected through this 
type of system can better position federal, state, and local health departments to more rapidly and 
comprehensively respond to the next public health emergency.
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Introduction
RECENT PUBLIC HEALTH emergencies have highlighted unique vulnerabilities of pregnant 
women and infants to emerging health threats and the critical role of public health 
surveillance. Surveillance systems can collect data to describe the impact of a disease or 
disaster that can be used to inform clinical guidance and prevention strategies.1
Pregnant women might be more susceptible to infection or experience more severe illness, 
mortality, pregnancy complications, or adverse birth outcomes.2 For example, during the 
2009–2010 H1N1 influenza pandemic, infected pregnant women had more severe illness 
and higher rates of hospitalization than the general population.3 Similarly, fetuses and 
infants may be at increased risk for adverse outcomes during public health emergencies, 
including stillbirth, preterm birth, low birthweight, birth defects, infant disorders, and 
developmental disabilities. For example, maternal Zika virus infection can cause serious 
brain and eye abnormalities in fetuses and infants and has been linked to 
neurodevelopmental disabilities in early childhood.4,5
Emerging threats to the health of pregnant women and infants are not limited to infectious 
diseases. Environmental exposures and natural disasters can introduce toxins (e.g., lead in 
the water supply), limit the supply of clean water and safe food, and may limit access to 
health care.6 Pregnant women and infants are also uniquely vulnerable populations impacted 
by the current opioid crisis. The rate of diagnosis of opioid use disorder at hospital delivery 
more than quadrupled between 1999 and 2014 in the United States.7 In parallel with 
increasing rates of maternal opioid use disorder, the rate of postnatal drug withdrawal among 
infants prenatally exposed to opioids, commonly known as neonatal abstinence syndrome 
(NAS), continues to increase. In 2014, a newborn with signs of opioid withdrawal was 
diagnosed every 15 minutes in the United States.8
Public health surveillance and the timely identification of known and emerging threats and 
evolving risks that affect pregnant women and infants enables federal, state, tribal, territorial, 
and local health departments to effectively respond to threats and mitigate adverse 
pregnancy, infant, and childhood outcomes. Rapid and complete characterization of the 
impact of health threats on pregnant women and their infants may benefit from an integrated 
surveillance system that (1) collects data on adverse maternal, pregnancy, and birth 
outcomes, such as birth defects or other infant disorders; (2) links the mother/infant dyad 
and collects data on pregnancy exposures; and (3) includes longitudinal monitoring to assess 
possible longer-term outcomes, such as cognitive impairment or developmental delay.
Rapid and real-time surveillance can quickly provide data to inform the public health 
response during an acute emergency, clinical practice guidelines for known and emerging 
threats, and the distribution of critical resources, including specialized health care. In 
addition, real-time data can monitor the effectiveness of prevention efforts and response 
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strategies, medical countermeasures, and other public health interventions in a timely 
manner.
In this report, we describe ongoing surveillance efforts to monitor congenital syphilis, Zika 
virus infection during pregnancy, and NAS and challenges within existing data systems (Fig. 
1).
We also discuss how an ongoing integrated surveillance system to monitor pregnant women 
and their infants can better position health agencies across the United States to more rapidly 
and comprehensively respond to the next public health emergency. As new health threats 
emerge and others resurge, this type of integrated surveillance system provides an 
innovative, efficient, and modifiable method to collect and exchange information and to 
inform public health strategies to protect pregnant women and infants. An overview of these 
topics was presented at CDC’s Public Health Grand Rounds on September 18, 2018.9
Congenital Syphilis
Syphilis is caused by the bacteria Treponema pallidum and is most often spread through 
sexual contact. Congenital syphilis occurs when an infected woman transmits syphilis to her 
fetus during pregnancy. Congenital syphilis can result in miscarriage, stillbirth, preterm 
birth, low birthweight, and infant death. Up to 40% of infants born to women with untreated 
syphilis may be stillborn or die from the infection as newborns.10 Infants born with 
congenital syphilis may experience anemia, hepatosplenomegaly, neurological impairment, 
including deafness, and birth defects of the long bones and teeth.11 When maternal syphilis 
is detected and appropriate treatment is initiated at least 30 days before delivery, congenital 
syphilis can be prevented.12
The Centers for Disease Control and Prevention (CDC) recommends universal syphilis 
screening at the first prenatal visit and additional screening for women at high risk, 
including those living in areas of high morbidity, between 28–32 weeks gestational age, and 
again at delivery to treat maternal syphilis and prevent congenital syphilis and its 
complications.13
Congenital syphilis is a nationally notifiable disease. Public health departments in all 50 
states, the District of Columbia, and all U.S. territories report cases of syphilis, including 
congenital syphilis, to CDC through the National Notifiable Diseases Surveillance System 
(NNDSS). CDC uses data reported to NNDSS to monitor syphilis trends, identify 
populations or geographic areas at high risk, plan prevention and control policies and 
interventions, and allocate resources.14 Despite the availability of effective treatment options 
that are safe for use during pregnancy, during 2012–2017, the number of infants born with 
congenital syphilis increased 176%.15,16
In 2017, CDC published a “Syphilis Call to Action” outlining critical gaps in syphilis 
surveillance and activities needed to reduce rates of syphilis, including the rate among 
women of reproductive age, which mirrors the rate of congenital syphilis. Female syphilis 
data collected and shared between health care providers, laboratories, and public health 
departments are essential for both treating women and preventing congenital syphilis.17 The 
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current surveillance system does not capture pregnancy status for women with syphilis in a 
timely manner. This limits state and local health departments’ ability to ensure prompt 
treatment at least 30 days before delivery and slows the triage of women into other 
preventive services, including health department-led case management programs.
The current surveillance system also makes identifying risk factors for congenital syphilis 
challenging because it does not link maternal and congenital syphilis cases and does not 
collect data on infants prenatally exposed to syphilis unless the infant is classified as a 
congenital syphilis case. Comparing infants born with congenital syphilis to infants who 
were prenatally exposed to syphilis but did not meet the case definition could identify 
protective factors to improve congenital syphilis prevention efforts. In addition, current 
surveillance methods do not collect data on children with prenatal syphilis exposure to 
assess possible longer-term effects.
A longitudinal surveillance system that enrolls pregnant women at the time of syphilis 
diagnosis could improve our understanding of developmental outcomes of children with 
prenatal syphilis exposure, ensure more complete congenital syphilis case ascertainment, 
allow us to examine maternal and fetal predictors of adverse outcomes, and link pregnant 
women to perinatal case management.
Zika Infection
Zika is a mosquito-borneflavivirus spread primarily through the bite of an infected Aedes 
species mosquito. Zika can also be spread through sexual transmission, blood transfusion, 
and from a woman to a fetus during pregnancy or at birth.18 Zika virus infection during 
pregnancy can cause severe brain and eye defects as well as other adverse outcomes 
secondary to neurological damage.4,5,19 In January 2016, CDC began an emergency 
response to outbreaks of Zika among immunologically naive populations in the Americas.20
In collaboration with health departments, CDC established the US Zika Pregnancy and 
Infant Registry and the Zika Birth Defects Surveillance system. These complementary 
surveillance systems provided more complete ascertainment of Zika-associated pregnancy 
and birth outcomes and improved our understanding of longer-term outcomes that could 
benefit from clinical follow-up during early childhood. The US Zika Pregnancy and Infant 
Registry prospectively monitors pregnant women and infants with laboratory evidence of 
possible Zika infection.21 The Zika Birth Defects Surveillance system retrospectively 
collects data on fetuses and infants born with Zika-associated birth defects with or without 
laboratory evidence of maternal Zika infection.22 Some jurisdictions were able to rapidly 
adapt their methods to report Zika-associated birth defects to CDC’s Zika Birth Defects 
Surveillance system, but this was only feasible on a short time frame among states with 
existing birth defects surveillance systems. Using 2013–2014 data from three state-based 
birth defects sur-veillance programs, CDC was able to estimate the baseline prevalence of 
birth defects potentially related to congenital Zika infection before the introduction of Zika 
in the Americas.23 This provided an important comparison to estimate the approximate 30-
fold increase in these specific birth defects among pregnancies with laboratory evidence of 
possible Zika virus infection.
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Data collected through the US Zika Pregnancy and Infant Registry and the Zika Birth 
Defects Surveillance system improved our understanding about the timing, risk, and 
spectrum of outcomes associated with Zika infection during pregnancy and enabled CDC to 
rapidly and continuously update travel, testing, and clinical care recommendations based on 
emerging data. In addition, data collected through these systems informed planning for 
clinical, public health, and other services needed to support pregnant women and families 
affected by Zika. The US Zika Pregnancy and Infant Registry continues to monitor infants 
and young children from >7400 completed pregnancies with laboratory evidence of possible 
Zika infection during pregnancy delivered between December 1, 2015 and March 31, 2018.
Collaboration between the US Zika Pregnancy and Infant Registry and the Zika Birth 
Defects Surveillance system resulted in a more robust understanding of the effects of Zika 
infection during pregnancy and informed clinical and public health efforts.1 However, there 
were also challenges. An early challenge to Zika surveillance was the absence of standard 
case definitions for Zika virus disease and congenital Zika infection.
At the start of the outbreak, states with existing birth defects surveillance programs were not 
collecting data on all birth defects associated with Zika infection in pregnancy. Therefore, 
states with existing birth defects surveillance programs needed to revise their existing 
methods. In addition, before the Zika response, relationships between some organizational 
units within state and local health departments were limited and required more intentional 
collaboration to share data across surveillance systems and with CDC.
In June 2016, the Council of State and Territorial Epidemiologists (CSTE), with input from 
CDC, established initial case definitions for congenital and noncongenital Zika virus disease 
and standardized data collection methods for cases of Zika virus infection across the United 
States.24 CDC also established a data use working group for the US Zika Pregnancy and 
Infant Registry to discuss issues around data reporting, analysis, and case definitions with 
state, local, and territorial partners.
States that successfully established remote access to hospital medical records for case 
abstraction reported a significant decrease in the amount of time and resources needed to 
collect and report data to the US Zika Pregnancy and Infant Registry and the Zika Birth 
Defects Surveillance system. Some states also reported that the multidisciplinary nature of 
the Zika response improved communication within and between health departments, as well 
as with health care providers, and led to more comprehensive case reports and improved 
communication of rapidly changing testing and treatment guidelines.
Neonatal Abstinence Syndrome
Prenatal opioid exposure is associated with poor fetal growth, preterm birth, stillbirth, and 
NAS, and some studies suggest a possible association with specific birth defects (e.g., 
orofacial clefts, gastroschisis).25-27 However, the potential longer-term impacts of prenatal 
opioid exposure are not well understood.
There is a strong body of evidence demonstrating that the teratogenic effects of alcohol use 
during pregnancy may not manifest until childhood or adolescence.28 Recent evidence 
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suggests that children born with NAS may be more likely to have a developmental delay or 
speech or language impairment in early childhood compared with children born without 
NAS.29 Longitudinal surveillance of children with prenatal opioid exposure could improve 
our understanding of possible teratogenic effects of opioid use during pregnancy and the 
confounding effects of exposure to other substances during pregnancy, including alcohol, as 
well as environmental and psychosocial factors.30
Currently, there is no national surveillance of NAS, but the recent establishment of a 
standardized surveillance case definition by CSTE is an opportunity to improve consistency 
and comparability of reported cases.31 As of January 3, 2018, six states had laws requiring 
reporting of NAS cases for public health surveillance.32 On January 10, 2018, 
Pennsylvania’s governor declared a statewide disaster emergency for the state’s heroin and 
opioid crisis. The declaration added NAS as a reportable condition for public health 
surveillance.33 In response, the Pennsylvania Department of Health rapidly established a 
statewide surveillance system to collect data on NAS cases.
Before the Zika emergency response, Pennsylvania was the largest state in the United States 
without a state-based birth defects surveillance system.34 However, in response to Zika, the 
state established a surveillance system to report cases to the US Zika Pregnancy and Infant 
Registry and the Zika Birth Defects Surveillance system. Establishing pregnancy and birth 
defects surveillance during the Zika response equipped the state to successfully implement 
data collection for NAS surveillance within a few weeks of the emergency declaration.
Specifically, the Pennsylvania Department of Health applied their familiarity of data 
elements captured in birth records to create an NAS case report form and quickly produced a 
list of birthing facilities and corresponding annual live birth counts to prioritize outreach and 
education on NAS case reporting. In addition, the Pennsylvania Department of Health 
rapidly adapted its web-based REDCap system used to report data to the US Zika Pregnancy 
and Infant Registry and the Zika Birth Defects Surveillance system for NAS data collection.
Building upon the Zika response’s investment and infrastructure enabled the Pennsylvania 
Department of Health to quickly distribute case reporting guidance to 95 birthing facilities 
and initiate rapid case ascertainment. Within 9 months, 89% (n = 85) of birthing facilities in 
Pennsylvania were reporting NAS cases to the Pennsylvania Department of Health.
NAS surveillance not only enabled the Pennsylvania Department of Health to estimate the 
incidence of NAS in their state but also provided information on maternal and infant 
characteristics, including maternal demographics, receipt of prenatal care, specific opioid 
exposures among NAS cases (e.g., medication-assisted treatment, synthetic opioids), 
symptoms of withdrawal (e.g., irritability, hypertonia), comorbidities among infants born 
with NAS (e.g., low birthweight, shorter length of gestation), and postnatal care 
administered to infants, including administration of pharmacological and non-
pharmacological treatment. The Pennsylvania Department of Health’s experience 
implementing a system for rapid NAS surveillance may offer strategies that other states 
could adopt to rapidly monitor NAS or other emerging health threats to pregnant women and 
infants.
Frey et al. Page 6
J Womens Health (Larchmt). Author manuscript; available in PMC 2019 August 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Summary and Future Directions
Surveillance is a core function of public health practice.35 The timely and systematic 
collection, analysis, and interpretation of data improves our ability to detect and respond to 
known and emerging health threats and can inform prevention practices and clinical 
guidance at both the patient and population level. Previous emergency responses as well as 
ongoing notifiable disease surveillance have demonstrated the benefits of public health 
surveillance data to inform prevention strategies and clinical care for pregnant women and 
infants.
However, we have too often ceased data collection on pregnant women and infants when an 
emergency response ends, limiting our ability to identify possible longer-term outcomes 
associated with public health threats to pregnant women and infants. Although NNDSS 
allows CDC to monitor the incidence and spread of specific infectious and noninfectious 
conditions, NNDSS does not collect pregnancy status for women who test positive for 
infection in a timely manner, does not link maternal cases to perinatal, neonatal, and 
pediatric outcomes, and does not collect longitudinal data.
Adverse outcomes associated with congenital syphilis, Zika infection during pregnancy, and 
NAS demonstrate vulnerabilities of pregnant women and infants and highlight the critical 
function of public health surveillance to protect these populations from known and emerging 
health threats. However, we do not have a comprehensive national surveillance system that 
(1) monitors adverse maternal and infant outcomes, including birth defects and other infant 
disorders; (2) links pregnancy exposure or infection data to longitudinal outcomes for 
mothers and infants; and (3) includes a longitudinal component to assess developmental 
outcomes among prenatally exposed children.
Existing public health surveillance efforts can be strengthened by consistent documentation 
and timely reporting of pregnancy status as part of laboratory testing and case reporting and 
may improve the treatment and management of maternal conditions during the prenatal 
period. In addition, as demonstrated during the Zika response, linking pregnancy data with 
infant outcomes can improve our understanding of outcomes associated with harmful 
exposures during pregnancy. This information can inform better prevention and clinical 
management and can help to standardize treatment protocols for pregnant women and 
infants.
This public health surveillance may also improve infant and child health. Longitudinal 
monitoring of exposed infants can help characterize risk factors for specific adverse 
outcomes, assess medical needs and possible developmental outcomes among children with 
specific prenatal exposures, and may facilitate screening for possible functional impairments 
that may benefit from treatments or interventions.
Building upon our experience with ongoing surveillance of notifiable diseases and lessons 
learned from surveillance of pregnant women and infants during emergency responses, CDC 
is working with partners to define core variables for future surveillance of known and 
emerging health threats to pregnant women and their infants that can be adapted using 
supplemental modules that might be needed for specific threats. A surveillance system with 
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these core variables could be poised to more rapidly respond to the next public health 
emergency and collect critical data to protect pregnant women and infants.
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Figure 1. Non-survey-based National Surveillance Systems for Maternal, Infant, and Child 
Health Outcomes
* This system collects case reports of syphilis infections in males and females; pregnancy 
status is reportable to national surveillance but is not collected in a timely manner.
†
 Established in 2016 as part of the Centers for Disease Control and Prevention Zika 
response.
§
 Additional birth defects were added to existing state-based birth defects surveillance 
systems for Zika Birth Defects Surveillance.
¶
 The Council of State and Territorial Epidemiologists established a position statement for a 
standardized surveillance case definition for neonatal abstinence syndrome surveillance that 
was approved in June.
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